(0.12%) 5 137.50 points
(0.07%) 38 466 points
(0.20%) 17 881 points
(-0.26%) $83.63
(1.82%) $1.958
(0.12%) $2 349.90
(0.44%) $27.66
(1.49%) $935.85
(-0.08%) $0.934
(-0.18%) $11.00
(-0.19%) $0.799
(1.28%) $93.05
@ $17.66
发出时间: 15 Feb 2024 @ 02:37
回报率: -6.17%
上一信号: Feb 15 - 01:03
上一信号:
回报率: 1.15 %
Live Chart Being Loaded With Signals
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access...
Stats | |
---|---|
今日成交量 | 321 644 |
平均成交量 | 527 866 |
市值 | 2.65B |
EPS | $0 ( 2024-02-29 ) |
下一个收益日期 | ( $0.100 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -47.34 |
ATR14 | $0.0120 (0.07%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Feehery William F | Buy | 124 779 | Restricted Stock Units |
2024-04-02 | Smith Patrick F | Sell | 5 264 | Common Stock |
2024-04-02 | Smith Patrick F | Sell | 649 | Common Stock |
2024-04-02 | Smith Patrick F | Sell | 3 024 | Common Stock |
2024-04-02 | Smith Patrick F | Sell | 328 | Common Stock |
INSIDER POWER |
---|
30.50 |
Last 100 transactions |
Buy: 798 344 | Sell: 442 671 |
音量 相关性
Certara, Inc. 相关性 - 货币/商品
Certara, Inc. 财务报表
Annual | 2023 |
营收: | $354.34M |
毛利润: | $167.79M (47.35 %) |
EPS: | $-0.350 |
FY | 2023 |
营收: | $354.34M |
毛利润: | $167.79M (47.35 %) |
EPS: | $-0.350 |
FY | 2022 |
营收: | $335.64M |
毛利润: | $203.07M (60.50 %) |
EPS: | $0.0939 |
FY | 2021 |
营收: | $286.10M |
毛利润: | $174.49M (60.99 %) |
EPS: | $-0.0900 |
Financial Reports:
No articles found.
Certara, Inc.
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。